Independent Equity Research & Structured Analysis, VASRO GmbH

VASRO GmbH

Independent Equity Research & Structured Analysis

VASRO Equity Research Reports provide independent, structured analysis on listed companies, with a focus on public small- and mid-cap issuers, under-covered companies, and cross-border equity stories. Reports typically include company positioning, sector context, financial and strategic analysis, key investor-relevant developments, methodology, and disclosure documentation. Coverage is maintained through recurring and event-driven updates. there are 2 types of ERs, deep-dive rated equity research and non-rated equity research.

Equity Bottom-Up

Sirnaomics is an RNA therapeutics biopharmaceutical company that discovers and develops innovative drugs for indications with unmet medical needs. The company leverages its proprietary polypeptide nanoparticle (PNP) and GalNAc RNAi platforms (GalAhead™) to build a pipeline of drug candidates, including STP705 and STP707 for oncology and fibrosis, and STP122G for anticoagulant therapies. Headquartered in Gaithersburg, MD, United States, the company was founded in 2007.

<ul><li>VASRO has published an update report on Sirnaomics Ltd. (HKEX: 2257) following the company’s announcement of 6 October 2026 and the FDA’s written responses of 10 September.</li><li>A state-owned fund, Guangzhou Guangjian, has paid RMB30m for 5.66% of RNAimmune’s Guangzhou subsidiary, and the deal was completed on 6 October. The price was set on an independent valuation of US$65.5m for RNAimmune Inc., the vaccine company in which Sirnaomics holds 60.21%. The money funds the subsidiary’s mRNA vaccine pipeline.</li><li>STP705, Sirnaomics’ lead drug for skin cancer, combines two gene-silencing molecules in one drug. In its written responses the FDA calls a four-arm Phase 2b study reasonable as an exploratory trial. The study compares the combination with each molecule alone and with placebo, and its results will shape the confirmatory Phase 3, the study on which approval rests.</li></ul>

VASRO has published an update report on Sirnaomics Ltd. (HKEX: 2257) following the company’s announcement of 6 October 2026 and the FDA’s written responses of 10 September.A state-owned fund, Guangzhou Guangjian, has paid RMB30m for 5.66% of RNAimmune’s Guangzhou subsidiary, and the deal was completed on 6 October. The price was set on an independent valuation of US$65.5m for RNAimmune Inc., the vaccine company in which Sirnaomics holds 60.21%. The money funds the subsidiary’s mRNA vaccine pipeline.STP705, Sirnaomics’ lead drug for skin cancer, combines two gene-silencing molecules in one drug. In its written responses the FDA calls a four-arm Phase 2b study reasonable as an exploratory trial. The study compares the combination with each molecule alone and with placebo, and its results will shape the confirmatory Phase 3, the study on which approval rests.

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705

Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its smelltech platform, powered by AI Nose and smell language model (SLM), digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Active clinical programs include HIV-related oral warts, primary Sjögren’s syndrome, and feline chronic gingivostomatitis (FCGS). Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age.

<ul><li>VASRO has published an update report on Ainos, Inc. (NASDAQ: AIMD) following the company’s VELDONA licence announcement of 24 September 2026 and its filing of 28 September.</li><li>Ainos has granted BioPhoenix Co., Ltd., a Taiwanese drug developer, an exclusive worldwide licence to its oral interferon platform for two indications, Sjögren’s disease and thrombocytopenia. BioPhoenix will fund and run the clinical and regulatory work assigned to it for those two indications; Ainos keeps ownership of the platform, its patents and its manufacturing know-how. In the annual report it filed in March, Ainos said it would primarily pursue out-licensing and partnerships to advance VELDONA. This is that step.</li><li>The framework carries a potential value of USD 10 million in three parts: an initial fee of USD 600,000 for the two indications, the fees for fifteen further licences if all are signed, and one fee on the first sublicence. Outside it, Ainos is entitled to 25% of net sublicensing revenue, so the framework is not a ceiling on what Ainos can earn. The structure also leaves Ainos more room to fund Chemical Intelligence, its first strategic priority.</li></ul>

VASRO has published an update report on Ainos, Inc. (NASDAQ: AIMD) following the company’s VELDONA licence announcement of 24 September 2026 and its filing of 28 September.Ainos has granted BioPhoenix Co., Ltd., a Taiwanese drug developer, an exclusive worldwide licence to its oral interferon platform for two indications, Sjögren’s disease and thrombocytopenia. BioPhoenix will fund and run the clinical and regulatory work assigned to it for those two indications; Ainos keeps ownership of the platform, its patents and its manufacturing know-how. In the annual report it filed in March, Ainos said it would primarily pursue out-licensing and partnerships to advance VELDONA. This is that step.The framework carries a potential value of USD 10 million in three parts: an initial fee of USD 600,000 for the two indications, the fees for fifteen further licences if all are signed, and one fee on the first sublicence. Outside it, Ainos is entitled to 25% of net sublicensing revenue, so the framework is not a ceiling on what Ainos can earn. The structure also leaves Ainos more room to fund Chemical Intelligence, its first strategic priority.

Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform

<ul><li>VASRO has published an update report on Ainos, Inc. following the company’s announcement of 14 September 2026.</li><li>Two facts arrived in the same release.</li><li>Ainos says it is receiving initial commercial orders from a front-end semiconductor company. Until this release, the last filed description of that work, in the quarterly report of 3 August, was pilot programs in selected front-end semiconductor environments. The validation programme, covering approximately 200 systems, was announced on 9 March 2026.</li></ul>

VASRO has published an update report on Ainos, Inc. following the company’s announcement of 14 September 2026.Two facts arrived in the same release.Ainos says it is receiving initial commercial orders from a front-end semiconductor company. Until this release, the last filed description of that work, in the quarterly report of 3 August, was pilot programs in selected front-end semiconductor environments. The validation programme, covering approximately 200 systems, was announced on 9 March 2026.

Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion

<ul>
<li>VASRO GmbH has initiated coverage of Sirnaomics Ltd. (HKEX: 2257) with a BUY recommendation and a target price of HK$7.07 per share.</li>
<li>Sirnaomics develops siRNA medicines, drugs that silence a disease-causing gene before it is turned into protein. The hard part is delivery, and beyond the liver very few groups can do it. The company owns two platforms: PNP, which it places among the world’s few extra-hepatic siRNA delivery systems with clinically proven safety, and GalAhead, which it describes as the only programmable RNAi platform for dosing intervals in global clinical development. Four programmes are in human trials, a fifth is IND-ready, and the company holds global rights across them.</li>
<li>The five years since listing were costly. Accumulated losses reached US$536.8m, spending was cut from US$91.8m in 2022 to US$15.3m in 2025, and headcount fell from 225 to 37. The audit opinion is qualified and going concern is flagged.</li>
</ul>


VASRO GmbH has initiated coverage of Sirnaomics Ltd. (HKEX: 2257) with a BUY recommendation and a target price of HK$7.07 per share.
Sirnaomics develops siRNA medicines, drugs that silence a disease-causing gene before it is turned into protein. The hard part is delivery, and beyond the liver very few groups can do it. The company owns two platforms: PNP, which it places among the world’s few extra-hepatic siRNA delivery systems with clinically proven safety, and GalAhead, which it describes as the only programmable RNAi platform for dosing intervals in global clinical development. Four programmes are in human trials, a fifth is IND-ready, and the company holds global rights across them.
The five years since listing were costly. Accumulated losses reached US$536.8m, spending was cut from US$91.8m in 2022 to US$15.3m in 2025, and headcount fell from 225 to 37. The audit opinion is qualified and going concern is flagged.


Sirnaomics Ltd: Every Approved SiRNA Drug Works in the Liver. This One Was Injected Into Skin Cancer

Baladna provides dairy products. The Company offers milk, cheese, cream, yoghurt, ghee, and dessert. Baladna serves customers in Qatar.

<ul><li>VASRO GmbH has published an update report on Baladna Q.P.S.C. (Qatar Stock Exchange: BLDN), reiterating its BUY recommendation with a target price of QAR 2.33 per share, revised from QAR 2.43 at initiation. Against the QAR 1.28 reference price the target implies 82.0% upside.</li><li>Investors subscribed for 415.5m of the 536.0m new shares Baladna offered, 77.5% of the issue. At QAR 1.01 a share that raised QAR 419.6m for growth in Qatar and in regional dairy.</li><li>The QAR 122m not raised is not a constraint. Baladna entered the second half with QAR 1,303.7m of liquid listed equity and a dairy business on course for QAR 421.7m of operating EBITDA this year, before portfolio fair-value gains and ahead of the company’s own guidance. The gap affects the timing of the expansion, not whether it proceeds.</li></ul>

VASRO GmbH has published an update report on Baladna Q.P.S.C. (Qatar Stock Exchange: BLDN), reiterating its BUY recommendation with a target price of QAR 2.33 per share, revised from QAR 2.43 at initiation. Against the QAR 1.28 reference price the target implies 82.0% upside.Investors subscribed for 415.5m of the 536.0m new shares Baladna offered, 77.5% of the issue. At QAR 1.01 a share that raised QAR 419.6m for growth in Qatar and in regional dairy.The QAR 122m not raised is not a constraint. Baladna entered the second half with QAR 1,303.7m of liquid listed equity and a dairy business on course for QAR 421.7m of operating EBITDA this year, before portfolio fair-value gains and ahead of the company’s own guidance. The gap affects the timing of the expansion, not whether it proceeds.

Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33